OCS entered the weekend down 23% — a collapse driven by a single late-Friday announcement.
The entire OCS story this week resolves to one event. After Friday's close, Oculis reported topline results from the DIAMOND-1 and DIAMOND-2 Phase 3 trials of OCS-01 eye drops in diabetic macular edema. The primary endpoint — best-corrected visual acuity — was not met in either study. The stock shed 23% on the day to close at $22.71, erasing what had been a constructive first half of May.
The borrow market is not what's interesting here, and short interest remains far too low to be the story. SI is just 0.87% of free float — rising 12% on the week as new shorts stepped in, but from a tiny base. Availability is still very loose at 508%, meaning more than five shares are available to borrow for every one already on loan. Cost to borrow, while up roughly 89% over the past month to 4.3%, is not high in absolute terms. None of those readings suggest a pre-positioned short attack; the bears simply weren't there in size.
Options positioning tells a more interesting tale in retrospect. The put/call ratio ended Friday at 0.47, well below its 20-day mean of 1.07. For most of the past month — from early May through mid-May — the PCR ran between 1.7 and 2.7, reflecting significant hedging. That protection was then unwound sharply in the days before the data readout, with calls dominating the tape in the final week. The PCR at the 52-week high reached 4.5 at some point in the past year; the swing from that level down to 0.47 heading into binary data is striking in hindsight.
The Street had been building conviction all month. JP Morgan raised its target to $42 from $38 while maintaining Overweight just last week. Guggenheim initiated with a Buy and a $75 target on May 21 — a notably aggressive call. Needham and HC Wainwright both raised targets to $46 and $47 respectively after Q1 earnings on May 12. Eight analysts carry Buy ratings, with a mean price target around $40.75. With OCS now trading at $22.71, the stock sits roughly 45% below the consensus target — but that target reflects pre-DIAMOND expectations and has not yet been updated for the trial failure. A wave of revisions is the obvious near-term event.
Institutional positioning adds context to how exposed the holder base is. EQT Fund Management is the largest holder at just under 10% of shares, having added 1.2 million shares in Q1. Millennium Management and Adage Capital both initiated positions in Q1 as well, with Millennium adding 897,000 shares. Those are relatively recent entry points; at $22.71, all three are sitting on meaningful losses against what were likely mid-to-high $20s cost bases.
The pipeline after DIAMOND is not empty — OCS still has OCS-02 in PREDICT-1 (Phase 2/3 for neuro-ophthalmic indications) and OCS-05 in development — and the next earnings are set for August 6. But the near-term focus is squarely on how the Street reprices those remaining assets, whether management outlines a capital allocation response, and whether any of the Q1 institutional buyers elect to add or exit at these levels.
See the live data behind this article on ORTEX.
Open OCS on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
